Instrument Inactif

Autres langues Cosmo Pharmaceuticals S.p.A Swiss Exchange

Actions

IT0004167463

Produits pharmaceutiques

Cours en clôture Swiss Exchange
- ^CHF	-

28/08	Au-delà de la balance : les hommes se tournent vers les cliniques esthétiques pour parachever leur perte de poids	RE
25/08	Bourse Zurich: optimisme mesuré avant l'ouverture des échanges	AW

Autres langues

28/08	Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
14/08	Cosmo ändert Tickersymbol an der SIX auf CMHC
14/08	Cosmo Pharmaceuticals to Adopt New Ticker on SIX Swiss Exchange
14/08	Cosmo Announces SIX Ticker Symbol Change to "CMHC"
11/08	Cosmo Pharmaceuticals Reports Phase 3 Results for Clascoterone Topical Solution for Male Hair Loss
23/07	Cosmo N.V. Reports Earnings Results for the Half Year Ended June 30, 2026
23/07	Cosmo N.V. Reaffirms Earnings Guidance for Full Year 2026
23/07	Aktien Schweiz: Nestlé zieht den SMI deutlich ins Minus
23/07	Cosmo mit weniger Umsatz im ersten Halbjahr
23/07	Cosmo Pharmaceuticals' H1 Loss Widens; Revenue Down
23/07	Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
01/07	Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
15/06	Cosmo Partner Introduces Winlevi Acne Product in Austria, Germany
15/06	Cosmo startet Aknecreme Winlevi in Österreich und Deutschland
15/06	Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany
11/06	Aktien Schweiz Vorbörse: Leichte Verluste - Warten auf EZB
11/06	Cosmo-Partner Glenmark startet Winlevi-Vertrieb in wichtigen EU-Märkten
11/06	Cosmo Pharmaceuticals Flags Launch of Acne Treatment in Key Markets Across Europe
11/06	Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
09/06	Berenberg Reiterates Cosmo Pharmaceuticals' Buy Rating on Partnership Potential
01/06	Aktien Schweiz Schluss: SMI verliert deutlich - Eskalation im Iran-Krieg
18/05	Cosmo Completes Patient Enrolment for Distal Ulcerative Colitis Trial
18/05	Cosmo schliesst Patientenaufnahme für Studie zu Colitis-Medikament ab
18/05	Cosmo N : Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program (DE)
18/05	Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program